Aticaprant for anhedonia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 22 Jun 2022: Trial started, NCT05455684
  2. 13 Jul 2022: Trial registered, NCT05455684
  3. 22 Sep 2022: Trial registered, NCT05550532
  4. 6 Dec 2022: Trial started, NCT05550532

The trials

NCT05455684: A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

State
Completed
Phase
Phase 3
People
513 taking part
Started
22 Jun 2022
Primary completion
18 Sep 2024
Arms
Aticaprant
Results
Posted on the registry
  1. 22 Jun 2022: Trial started
  2. 13 Jul 2022: Trial registered
  3. 18 Sep 2024: Trial completed
  4. 6 Nov 2025: Trial results posted

NCT05550532: A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

State
Completed
Phase
Phase 3
People
444 taking part
Started
6 Dec 2022
Primary completion
8 Nov 2024
Arms
Aticaprant
Results
Posted on the registry
  1. 22 Sep 2022: Trial registered
  2. 6 Dec 2022: Trial started
  3. 13 Nov 2024: Trial completed
  4. 2 Jan 2026: Trial results posted

NCT06514742: A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

State
Stopped early
Phase
Phase 3
People
101 taking part
Started
26 Jun 2024
Primary completion
8 Apr 2025
Arms
Aticaprant
Results
None posted
  1. 26 Jun 2024: Trial started
  2. 23 Jul 2024: Trial registered
  3. 24 Apr 2025: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as JNJ-67953964.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.